Alvotech (ALVO)
NASDAQ: ALVO · IEX Real-Time Price · USD
11.91
-0.18 (-1.49%)
Jul 11, 2024, 4:30 PM EDT - Market closed

Company Description

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.

It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.

In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product.

Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Alvotech
Alvotech logo
Country Iceland
Founded 2013
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,026
CEO Robert Wessman

Contact Details

Address:
9, Rue De Bitbourg
Luxembourg, N4 L-1273
Luxembourg
Phone 354 422-4500
Website alvotech.com

Stock Details

Ticker Symbol ALVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001898416
CUSIP Number L01800108
ISIN Number LU2458332611
Employer ID 98-1629342
SIC Code 2836

Key Executives

Name Position
Robert Wessman Chief Executive Officer, Founder and Executive Chairman
Faysal Kalmoua Chief Operating Officer and Director
Joel Morales Chief Financial Officer
Giedrius Zunda Chief Technical Officer
Joseph E. McClellan Chief Scientific Officer
Tanya Zharov General Counsel
Anil Okay Chief Commercial Officer
Ming Li Chief Strategy Officer
Christina Siniscalchi Chief Quality Officer

Latest SEC Filings

Date Type Title
Jul 11, 2024 6-K Report of foreign issuer
Jul 3, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jul 3, 2024 6-K Report of foreign issuer
Jul 2, 2024 6-K Report of foreign issuer
Jul 1, 2024 6-K/A Filing
Jul 1, 2024 6-K Report of foreign issuer
Jun 26, 2024 RW Filing
Jun 26, 2024 6-K Report of foreign issuer
Jun 18, 2024 6-K Report of foreign issuer
Jun 14, 2024 6-K Report of foreign issuer